Von Willebrand factor (VWF) does two things in hemostasis: it plugs gaps in damaged vessel walls by tethering platelets to collagen, and it acts as a carrier protein for coagulation Factor VIII¹¹ coagulation Factor VIII
Factor VIII is the key cofactor in the intrinsic coagulation cascade (tenase complex). Without it, secondary hemostasis — clot reinforcement — fails, producing the hemophilia A phenotype. VWF normally stabilises circulating FVIII and delivers it to the site of vascular injury. The rs41276738 variant disrupts this second role: the scaffold is structurally normal, but it cannot hold its cargo.

The Mechanism

The D' domain of VWF — encoded by exon 18 — is the high-affinity binding site for Factor VIII. Arginine at position 854 is a critical contact residue in this binding pocket. The Arg854Gln substitution (R854Q) replaces this positively charged arginine with a neutral glutamine, disrupting the electrostatic interface between VWF and FVIII without altering VWF secretion, multimer structure, or platelet-tethering activity.

The consequence is type 2N (Normandy) von Willebrand disease²² type 2N (Normandy) von Willebrand disease
Named after the French region where the original kindreds were identified; also called VWD type 2 Normandy. Characterized by markedly reduced VWF affinity for FVIII with normal platelet-dependent hemostasis. FVIII is under-stabilised in circulation and cleared more rapidly, producing reduced plasma FVIII levels — often in the range of 5–30 IU/dL in homozygotes — that precisely mimic mild-to-moderate hemophilia A. VWF antigen and ristocetin cofactor activity are normal or only mildly reduced.

The inheritance pattern is codominant with dose dependency: heterozygous CT carriers have a partial FVIII-binding defect (reduced VWF:FVIIIB/VWF:Ag ratio) that is detectable with laboratory testing but rarely causes spontaneous bleeding. Homozygous TT or compound heterozygous states produce the full clinical phenotype.

The Evidence

Van den Biggelaar et al. (2009)³³ Van den Biggelaar et al. (2009) demonstrated that Arg854Gln causes a moderate FVIII-binding defect in cell studies: unlike severe type 2N mutations (Thr791Met, Arg816Trp), Arg854Gln VWF still traffics to Weibel-Palade bodies and co-recruits FVIII into storage organelles, but FVIII release and stabilisation are compromised. This helps explain why homozygous R854Q patients have less severe FVIII deficiency than those carrying null-allele combinations.

Casonato et al. (2018)⁴⁴ Casonato et al. (2018) conducted a 15-year analysis of 2,178 VWF:FVIIIB assays and found the p.R854Q heterozygous carrier frequency at ~5.2% in northeast Italy — far above the rate one would expect from rare disease status. The VWF:FVIIIB/VWF:Ag ratio was consistently abnormal in carriers, making it the most reliable screening tool.

Daniel et al. (2024)⁵⁵ Daniel et al. (2024), in the largest type 2N cohort to date (123 French patients), stratified outcomes by R854Q genotype. Homozygous R854Q patients (n=55) had significantly higher residual FVIII than compound heterozygotes with null alleles (p<0.0001), and experienced heterogeneous desmopressin responses — with baseline FVIII level predicting desmopressin efficacy. The study confirms genotype-driven phenotype stratification and underscores the need for individualised DDAVP trials.

Practical Actions

The key clinical challenge is that type 2N VWD is routinely misdiagnosed as mild hemophilia A because the laboratory phenotype (low FVIII, normal aPTT when borderline) is identical. The distinguishing test is the VWF:FVIII binding assay (VWF:FVIIIB) — specifically the VWF:FVIIIB/VWF:Ag ratio, which is abnormal even in heterozygous carriers. Molecular confirmation by sequencing VWF exon 20 (where codon 854 resides) should follow any abnormal binding assay.

For homozygous TT carriers, the treatment algorithm differs critically from hemophilia A: desmopressin (DDAVP) acts on endothelial Weibel-Palade body release to transiently raise VWF and co-released FVIII; it can be effective in type 2N but response is variable and must be individually assessed. VWF concentrate (not FVIII concentrate alone) is the treatment of choice when desmopressin is inadequate, because it provides exogenous VWF capable of stabilising endogenous or infused FVIII at the injury site.

Interactions

The ABO blood group locus (rs505922 and related variants) is the strongest known modifier of circulating VWF levels: blood group O individuals have ~25% lower VWF antigen than non-O. In type 2N heterozygotes, who already have a partial FVIII-binding defect, co-inheritance of blood group O may further reduce functional VWF:FVIIIB, compounding the bleeding risk. Full haemostatic phenotype assessment should include ABO blood typing.

Compound heterozygosity — one R854Q allele combined with a null VWF allele (type 1/3 mutations, frame-shifts, or splice variants) — produces a more severe phenotype than R854Q homozygosity, because the null allele contributes no functional VWF while the R854Q allele secretes VWF unable to bind FVIII. Hilbert et al. (2006)⁶⁶ Hilbert et al. (2006) documented such compound heterozygosity with undetectable VWF:FVIIIB and an abnormal multimer profile.

Endometriosis affects an estimated 10% of women of reproductive age, yet on average it takes 4–11 years from first symptoms to confirmed diagnosis¹¹ 4–11 years from first symptoms to confirmed diagnosis
Diagnosis requires laparoscopic surgery; symptoms are routinely attributed to normal menstrual pain. Among the mechanisms proposed to explain why displaced endometrial cells survive and implant outside the uterus, cell adhesion stands out: ectopic cells must attach to peritoneal surfaces, evade immune clearance, and establish a blood supply. The VEZT gene encodes one of the proteins that makes that adhesion possible.

rs4762326 sits within an intron of VEZT (vezatin, adherens junctions transmembrane protein) on chromosome 12q23.2. It is one of the most consistently replicated common genetic signals for endometriosis discovered to date, having been identified or confirmed in multiple independent GWAS cohorts spanning European, East Asian, and admixed populations.

The Mechanism

Vezatin is a ubiquitous transmembrane component of adherens junctions — the molecular structures that anchor epithelial cells to one another and to the extracellular matrix. It forms part of the cadherin–catenin complex at cell-cell contact sites, linking actin cytoskeleton dynamics to epithelial stability and cell migration. In ectopic endometrial tissue, dysregulated adherens junction activity may lower the energy barrier for implantation on non-uterine surfaces such as the peritoneum, ovaries, and bowel serosa.

The rs4762326 T allele is intronic, so it does not change the vezatin amino acid sequence directly. Instead, it likely alters VEZT transcription or splicing in endometrial stromal and epithelial cells — potentially up-regulating cell adhesion capacity during the retrograde menstruation cycle phase when endometrial fragments are shed into the peritoneal cavity. Functional studies characterizing the exact regulatory effect of this intronic variant are ongoing; the biological plausibility of VEZT as an endometriosis susceptibility gene is supported by the consistent genetic association and the central role adherens junctions play in ectopic implantation.

The Evidence

The clearest quantification of this variant's effect comes from a meta-analysis of 17,045 endometriosis cases and 191,596 controls across eleven GWAS datasets²² meta-analysis of 17,045 endometriosis cases and 191,596 controls across eleven GWAS datasets
Sapkota et al. Nature Communications, 2017. The T allele at rs4762326 reached genome-wide significance for endometriosis overall (OR 1.08, 95% CI 1.05–1.11, p = 2 × 10⁻⁹) and was nominally significant in the European-ancestry subset (OR 1.07, p = 1 × 10⁻⁶). The T allele frequency was 0.47 in this dataset. In the Japanese-ancestry arm of the same study, the rare G allele at this multiallelic position showed an OR of 1.22, though the G allele is essentially absent in non-Asian populations (frequency < 0.001 in gnomAD global data).

The locus was independently prioritized at substantially higher significance (p = 4 × 10⁻¹⁴) in a 2023 GWAS of shared genetic architecture across gynaecological disorders³³ 2023 GWAS of shared genetic architecture across gynaecological disorders
Kiewa et al. Neuroendocrinology, 2023, confirming rs4762326 as the top locus in analyses jointly modelling endometriosis, uterine fibroids, ovarian cysts, menorrhagia, and menopausal symptoms.

The 2023 Nature Genetics meta-analysis by Rahmioglu and colleagues⁴⁴ 2023 Nature Genetics meta-analysis by Rahmioglu and colleagues, the largest endometriosis GWAS to date, further established the genetic comorbidity of endometriosis with chronic pain and inflammatory conditions, a context consistent with VEZT's role in the inflammatory peritoneal microenvironment surrounding ectopic implants.

An OR of 1.08 per allele is modest in absolute terms but robust across diverse cohorts. The consistent replication across European and East Asian populations — despite very different T allele frequencies — strengthens the biological interpretation: this is not a population-specific variant but a genuine pleiotropic signal in the biology of ectopic endometrial cell implantation.

Practical Implications

The T allele at rs4762326 raises the population probability of endometriosis modestly. For individual risk counselling, the primary value of this result is raising awareness of endometriosis symptoms and supporting a lower threshold for timely investigation — rather than serving as a diagnostic marker in isolation.

Women with this variant who experience hallmark symptoms — dysmenorrhea disrupting daily function, deep dyspareunia, cyclic pelvic or bowel pain, or unexplained sub-fertility — should escalate to specialist evaluation rather than accept symptom normalization. The typical diagnostic gap of nearly a decade is driven by clinicians and patients both underestimating pain severity; genetic awareness can help counteract that bias.

Interactions

rs12700667 (7p15.2 locus, near HOXA10/HOXA11): The 7p15.2 locus is one of the most strongly replicated endometriosis susceptibility signals, with an OR of 1.20 for any endometriosis and 1.38 for moderate-to-severe disease. Both loci contribute to endometriosis risk through different biological pathways — rs12700667 likely through HOX gene-mediated endometrial programming, rs4762326 through cell adhesion capacity. Women carrying risk alleles at both loci may have additive susceptibility, though no formal gene-gene interaction paper has been published for this pair.

rs7521902 (WNT4 locus): WNT4 is one of the most significantly associated endometriosis loci (OR up to 1.21) and also implicates cell signalling in endometrial tissue specification. The combination of a cell adhesion variant (VEZT, rs4762326) and a cell signalling variant (WNT4, rs7521902) in the same individual would represent two mechanistically distinct contributions to ectopic implantation risk.

rs1250248 (FN1 — fibronectin 1): FN1 encodes fibronectin, a major extracellular matrix glycoprotein that interacts directly with cell surface adhesion receptors. An epistatic interaction between the FN1 locus and WNT4 has been described for ovarian endometriosis. Fibronectin and vezatin operate in adjacent layers of the adhesion machinery; carrying variants in both genes could further amplify ectopic implantation efficiency.

For a supervisor compound action proposal: women carrying both the rs4762326 T allele (VEZT cell adhesion) and the rs12700667 A allele (7p15.2/HOX regulation) represent a plausible high-risk subgroup for endometriosis monitoring. Combined recommendation: lower threshold for specialist gynecological evaluation at first symptom onset, and proactive baseline AMH and antral follicle count by age 28. Evidence level: moderate (both loci established; combined effect is additive assumption, not formally tested).

Every menstrual cycle, hundreds of follicles begin to grow but only one (occasionally two) is selected to ovulate. The rest undergo programmed destruction — a process called follicular atresia¹¹ follicular atresia
the apoptotic elimination of follicles that fail the selection process; accelerated atresia reduces ovarian reserve and is implicated in PCOS, diminished ovarian reserve, and early menopause — and the rate at which this culling occurs determines how rapidly the ovarian reserve depletes over a woman's reproductive lifespan. PRSS23²² PRSS23
serine protease 23; a conserved trypsin- family endopeptidase expressed in granulosa cells, theca tissue, and atretic follicles; located at chromosome 11q14.2 is one of the enzymes that carries out this culling. The rs4944653-G variant, located approximately 50 kilobases downstream of the PRSS23 gene, tags a regulatory signal that amplifies PRSS23 activity — and the consequences show up in measurable changes in circulating FSH.

The Mechanism

PRSS23 is expressed primarily in granulosa cells of secondary and early antral follicles — the very cells responsible for producing estrogen and expressing FSH receptor (FSHR). A 2026 study in avian granulosa cells³³ A 2026 study in avian granulosa cells
Wang et al. PRSS23 Promotes Ovarian Follicular Atresia in Wuding Chickens by Coordinately Suppressing Steroidogenesis and PI3K/AKT/mTOR Survival Signaling. Genes (Basel), 2026 showed that PRSS23 overexpression simultaneously downregulates FSHR and the steroidogenic enzymes CYP19A1, StAR, and HSD3β1, while activating the mitochondrial apoptotic pathway (increasing BAX, decreasing BCL2) via PI3K/AKT/mTOR inhibition. The result is cell cycle arrest and granulosa cell death — the molecular signature of atresia.

Critically, PRSS23 expression is downregulated by gonadotropins near the time of ovulation, ⁴⁴ Wahlberg et al. Expression and localization of the serine proteases HtrA1, SP23, and SP35 in the mouse ovary. Endocrinology, 2008 suggesting FSH normally suppresses this atretic enzyme to protect dominant follicles. When the rs4944653-G allele increases PRSS23 expression in the follicular microenvironment, the pituitary must compensate by producing more FSH to overcome amplified atretic pressure — hence the higher serum FSH seen in G carriers.

The Evidence

The clearest human evidence comes from Tidwell et al. 2024⁵⁵ Tidwell et al. 2024
Phenotypes Associated With Polycystic Ovary Syndrome Risk Variants. J Endocr Soc, 2024, a study of 404 PCOS cases and 408 controls from the Utah PCOS cohort. The rs4944653-G allele showed a strict dose-response relationship with FSH levels: AA carriers averaged 9.0 ± 3.1 IU/L, AG carriers 9.5 ± 3.2 IU/L, and GG homozygotes 10.7 ± 4.6 IU/L. The association survived adjustment for both age (beta 0.040 ± 0.010, P<.001) and BMI (beta 0.041 ± 0.010, P<.001), confirming it is not mediated by obesity — a key distinction in a PCOS population.

The PRSS23 locus was also among the loci associated with gonadotropin levels in this study, alongside the well-established FSHB locus. The G allele is common: approximately 62% of women globally are GG homozygotes, and a further 33% are AG heterozygotes, meaning fewer than 5% of women carry the AA (lowest-FSH) genotype.

The broader PCOS genetic architecture was established by the Day et al. 2018 meta-analysis⁶⁶ Day et al. 2018 meta-analysis
Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genetics, 2018, which identified 14 genome-wide significant loci across 10,074 cases and 103,164 European-ancestry controls. PRSS23-region variants sit within this PCOS risk landscape, providing the biological rationale for the FSH association: elevated FSH in the absence of ovarian failure may reflect a continuous push against increased follicular atresia at the granulosa cell level.

Practical Actions

For women with one or two copies of the G allele, the elevated FSH signal has two actionable implications. First, standard FSH thresholds used to assess ovarian reserve (the commonly used "normal < 10 IU/L" cut-off) may need to be contextualised genetically — a GG woman with FSH of 10.5 IU/L may be within her genotype-normal range rather than showing early diminished ovarian reserve. Second, women with GG genotype and PCOS should discuss whether their FSH level is primarily driven by genetic background or by PCOS- related gonadotropin dysregulation, as this distinction affects treatment decisions.

Anti-Müllerian hormone (AMH) — which reflects the number of remaining antral follicles and is not directly influenced by this PRSS23 variant — provides a complementary measure of ovarian reserve that is unconfounded by this genetic background FSH elevation.

Interactions

The rs4944653 PRSS23 variant acts through the FSH axis and thus interacts conceptually with variants in the FSHB gene (rs11031006, which directly encodes the FSH beta subunit) and with ovarian reserve variants such as HELQ rs12651246. A woman carrying both elevated- FSH PRSS23 genotype and a FSHB variant would be expected to show compounded gonadotropin dysregulation, though direct interaction studies have not yet been published.

The PCOS susceptibility locus ZBTB16 (rs1784692) and the PRSS23 locus both appear in the Tidwell et al. 2024 study, and while they affect different PCOS phenotypic features (ovarian morphology vs. FSH levels respectively), women carrying risk alleles at both loci may present with a more complete PCOS endocrine profile.

The heart is not only a pump — it's an endocrine organ that actively regulates blood pressure. When the atria stretch under elevated pressure, cardiac cells release atrial natriuretic peptide (ANP)¹¹ atrial natriuretic peptide (ANP)
a hormone that signals the kidneys to excrete sodium and water, dilates blood vessels, and suppresses the renin-angiotensin system. ANP is the body's built-in counter-regulatory brake against hypertension. The rs5068 variant in the 3' untranslated region of the NPPA gene determines how efficiently this brake operates. Carriers of the minor G allele produce substantially more ANP — and enjoy a broad spectrum of cardiovascular and metabolic benefits as a result.

The Mechanism

The 3' UTR of an mRNA contains binding sites for microRNAs²² microRNAs
small non-coding RNA molecules that bind to mRNA and suppress its translation into protein. The rs5068 A allele (carried by ~89% of people) contains a perfect binding site for miR-425, which is expressed in cardiac atria and ventricles. When miR-425 binds, it silences NPPA mRNA — reducing ANP secretion by up to 56% in experimental cardiomyocytes.

The G allele disrupts this binding site through a single nucleotide change. In cells carrying the G allele, miR-425 cannot bind, and NPPA mRNA escapes suppression. In vitro³³ In vitro
laboratory cell studies confirmed that miR-425 reduces NPPA expression in A-allele constructs but not G-allele constructs (P = 0.005). In physiologic studies, AG individuals showed 32-50% higher circulating Nt-proANP compared to AA individuals — a difference comparable in magnitude to the ANP change induced by a 20-fold dietary salt variation.

The Evidence

The foundational Nature Genetics GWAS⁴⁴ Nature Genetics GWAS
a genome-wide association study pooling 29,717 European-ancestry participants established rs5068 as one of the strongest genetic determinants of circulating natriuretic peptide levels (P = 8×10⁻⁷⁰ for ANP; P = 3×10⁻¹² for BNP). The G allele was associated with lower systolic blood pressure (P = 2×10⁻⁶), lower diastolic blood pressure (P = 1×10⁻⁶), and a 15% lower odds of hypertension (OR 0.85, 95% CI 0.79-0.92).

A community-based JACC study⁵⁵ community-based JACC study
n=1,608 residents of Olmsted County, Minnesota, followed prospectively found G allele carriers had lower systolic blood pressure (−4.3 mmHg), lower BMI (−1.2 kg/m²), smaller waist circumference (−2.5 cm), lower obesity odds (OR 0.54), higher HDL cholesterol (+2.5 mg/dL), lower CRP, and strikingly lower odds of myocardial infarction (OR 0.29, P = 0.042).

In a Mediterranean population⁶⁶ Mediterranean population
n=804 adults from rural Sicily, adjusted for age, sex, and BMI, G allele carriers showed 6.0 mmHg lower systolic blood pressure (P = 0.02), 3.0 mmHg lower diastolic (P = 0.03), and a 59% lower odds of hypertension (OR 0.41, 95% CI 0.20-0.83).

The Malmö Preventive Project⁷⁷ Malmö Preventive Project
n=968 non-diabetic older adults with echocardiography data demonstrated that G allele carriers had significantly less left ventricular hypertrophy — an ominous cardiac remodeling response to chronic pressure overload — with an OR of 0.47 (95% CI 0.25-0.89).

Protection extends to metabolic health. A large Swedish prospective cohort⁸⁸ large Swedish prospective cohort
n=27,307 from the Malmö Diet and Cancer Study, 14 years follow-up found G allele carriers had 12% lower hazard of developing type 2 diabetes (HR 0.88, 95% CI 0.78-0.99). ANP directly activates hormone-sensitive lipase in adipose tissue via a cGMP-dependent pathway, promoting fat oxidation and improving insulin sensitivity.

The protective effect extends across ethnicities. In African American MESA participants⁹⁹ African American MESA participants
n=1,631 from the Multi-Ethnic Study of Atherosclerosis, G allele carriers had lower metabolic syndrome prevalence (23% vs 38%) and lower triglycerides, though the blood pressure association was not significant in this population.

Practical Actions

The AA genotype — carried by most people — means the miR-425 brake operates fully, keeping ANP levels lower. This doesn't cause disease on its own, but it means the natural ANP-mediated counterbalance to salt loading and blood pressure elevation is somewhat blunted. Practical strategies center on reducing the need for ANP (lower sodium load, support vascular tone through dietary nitrates) and monitoring blood pressure proactively.

G allele carriers produce more ANP and enjoy measurably lower blood pressure and metabolic protection. No specific interventions are needed for the protective genotype — the key insight is understanding why your blood pressure runs lower and why your metabolic profile is favorable.

Interactions

NPPA and NPPB (which encodes BNP) lie in tandem on chromosome 1p36 and are co-regulated. The NPPB variant rs198389 similarly influences BNP levels and blood pressure. Haplotype analyses show that combinations of NPPA rs5068 G and NPPB rs198389 G produce additive elevations in circulating natriuretic peptides. Sex modifies the metabolic protection: in a general community cohort, the ANP protection from rs5068 was more pronounced in men than women, while BNP protection (rs198389) tended toward women.

The C2 gene encodes complement component 2, a serine protease that is indispensable for activating the classical complement pathway¹¹ classical complement pathway
the arm of innate immunity triggered by antibody-antigen complexes and certain pathogens. rs547154, also called IVS10 (intron variant 10), sits in an intron — a non-coding stretch of DNA that is spliced out before the protein is made. Yet this quiet intronic change is one of the most robustly replicated protective variants in ocular genetics, because it tags a specific chromosomal block that fundamentally alters how the complement system responds in ageing retinal tissue.

The Mechanism

rs547154 itself (G>T on the plus strand) does not change any amino acid in the C2 protein. Its power derives from haplotype context: it is inherited in extremely tight linkage disequilibrium (r²≈0.92–0.96) with the CFB R32Q missense variant (rs4151667)²² CFB R32Q missense variant (rs4151667)
the functional variant in complement factor B that reduces C2/CFB complex activity. Together, rs547154-T and CFB R32Q-A constitute the H7 protective haplotype — a segment of the HLA class III region on chromosome 6p21.3 that is inherited as a unit and reduces the efficiency of the classical complement pathway.

The classical pathway begins when C1q binds antibody-coated targets. C1 then cleaves C4 and C2, generating the C3 convertase (C4b2a) that splits C3 into C3b (opsonin) and C3a (anaphylatoxin). The R32Q substitution in CFB produces a less stable C3 convertase with reduced catalytic activity, blunting the entire downstream cascade. Less C3 cleavage means fewer complement fragments accumulate in the retinal pigment epithelium, reducing chronic sub-retinal inflammation and drusen formation — the hallmarks of early AMD.

rs547154 itself may additionally influence C2 expression through intronic regulatory elements, though this has not been fully characterised. The strong LD with CFB R32Q means separating their independent contributions requires conditional analyses that go beyond most published studies.

The Evidence

The H7 haplotype was first described in Gold et al. 2006 in Nature Genetics³³ Gold et al. 2006 in Nature Genetics
case-control study of ~900 AMD cases and ~400 controls: the haplotype carried an odds ratio of 0.45 (95% CI 0.33–0.61) for AMD risk, independent of age, CFH Y402H, and ARMS2/HTRA1. The combined model of C2/CFB haplotype plus CFH variants correctly classified 74% of AMD cases and 56% of controls — a remarkable predictive accuracy for a complex disease.

The individual rs547154 signal has since been replicated across populations and study designs. A HuGE meta-analysis of 19 studies⁴⁴ HuGE meta-analysis of 19 studies
Thakkinstian et al. 2012 found an odds ratio of 0.47 (95% CI 0.39–0.57) for the T allele, translating to a 2–6% absolute risk reduction in Caucasian cohorts. A separate meta-analysis of 15 studies covering 8,905 subjects⁵⁵ meta-analysis of 15 studies covering 8,905 subjects
Sun et al. 2012 found the dominant model OR of 0.40 (95% CI 0.29–0.55), meaning T carriers have roughly 60% of the AMD risk compared to GG individuals. The Lu et al. 2018 mega-analysis⁶⁶ Lu et al. 2018 mega-analysis
53,774 AMD cases and 56,973 controls across 53 studies confirmed the heterozygote OR of 0.52 (95% CI 0.43–0.62), with the strongest protection in Caucasians.

Protection extends beyond classic AMD. A meta-analysis of 4,076 subjects including polypoidal choroidal vasculopathy (PCV) cases⁷⁷ 4,076 subjects including polypoidal choroidal vasculopathy (PCV) cases
Chen et al. 2015 found the T allele equally protective against PCV (OR 0.64, p<0.0001), with no statistical difference between AMD and PCV subgroups. The effect replicates in Japanese populations⁸⁸ Japanese populations
Mori et al. 2012 (AMD OR 0.47, PCV OR 0.53, both p<0.01) and in Indian populations⁹⁹ Indian populations
Kaur et al. 2010 (protective haplotype OR 0.10, p=5.4×10⁻¹¹), demonstrating a cross-ethnic biological signal.

The variant is notably absent from AMD associations in some smaller populations (e.g. a Greek cohort of 260 subjects), likely because of low statistical power at the low T-allele frequency.

Practical Implications

For T allele carriers, this variant reduces complement-mediated retinal inflammation independent of other AMD risk loci. However, it does not confer immunity: AMD can still develop, particularly in those who smoke, carry CFH Y402H risk genotypes, or have other AMD risk factors. The protection is graded — one T allele gives roughly 50% risk reduction; two T alleles (rare) give maximum protection from this locus.

For GG homozygotes — about 83% of Europeans — this protective mechanism is absent, meaning AMD risk from this locus is unmodified. GG individuals should focus on other modifiable risk factors: smoking cessation, dietary carotenoids, omega-3 fatty acids, and regular ophthalmological surveillance.

Interactions

rs547154 acts in tight concert with CFB rs4151667 (R32Q) as the H7 haplotype. This is a distinct signal from the H10 haplotype tagged by C2 E318D (rs9332739) + CFB L9H (rs1270942). Both haplotypes reduce complement activation but through different structural perturbations in the C2/CFB complex and are inherited independently, so an individual can carry one, both, or neither.

The H7 haplotype protection is independent of and additive with the CFH Y402H (rs1061170) signal — the two variants operate at different nodes of the complement cascade (CFH regulates the C3 convertase at the alternative pathway level; C2/CFB modulates classical pathway C3 convertase assembly). C3 R102G (rs2230199) adds a third independent AMD risk locus in the same pathway. Individuals who carry the H7 haplotype and lack CFH risk alleles have the strongest overall complement protection; those who carry CFH risk alleles but also carry the H7 haplotype experience partial but meaningful buffering of their AMD risk.

CYP17A1¹¹ CYP17A1
cytochrome P450 17A1, encoding the bifunctional enzyme 17α-hydroxylase/17,20-lyase sits at one of the most critical branch points in human steroid biosynthesis. The enzyme converts pregnenolone and progesterone to 17-hydroxy intermediates (generating cortisol precursors) and catalyzes the subsequent lyase reaction that produces DHEA and androstenedione — the precursors to all androgens and estrogens. rs6162 is a synonymous coding variant at codon 46 of CYP17A1 (c.138C>T, His46=), meaning it does not change the encoded amino acid. Its biological significance is primarily as a haplotype-tagging SNP: it co-occurs in strong linkage disequilibrium with the 5'UTR variant rs743572 (T-34C)²² rs743572 (T-34C)
rs743572 lies 171 bp upstream of rs6162 and creates an Sp1 transcription factor binding site that alters CYP17A1 promoter activity, and the rs6162 A allele effectively tags the CYP17A1 haplotype associated with altered enzyme expression and steroid output.

The Mechanism

The rs6162 A allele (synonym: the CAT codon at position 46 vs. the reference CAC codon; both encode histidine) does not directly alter CYP17A1 protein function. Rather, it resides in strong LD with regulatory variants in the CYP17A1 locus — most notably rs743572 (T-34C), which creates an additional Sp1 binding site in the promoter region and is associated with increased transcription of the enzyme in some in vitro systems. Variants in this haplotype block influence how much CYP17A1 protein is produced, altering flux through the 17α-hydroxylase and 17,20-lyase reactions. The lyase step is rate-limiting for DHEA synthesis; increased CYP17A1 activity pushes more steroid substrate toward the Δ5 pathway³³ Δ5 pathway
the androgen biosynthesis pathway through DHEA and androstenedione, as opposed to the Δ4 glucocorticoid pathway and away from cortisol precursors. The downstream effects include elevated DHEA-S and, through peripheral conversion, raised androgen levels — an effect directly relevant to prostate cancer biology and androgen signaling in general.

The Evidence

The most rigorous study of rs6162 is Lévesque et al. 2013 in Clinical Cancer Research⁴⁴ Lévesque et al. 2013 in Clinical Cancer Research
Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. Clin Cancer Res 19:699–709, which genotyped 109 haplotype-tagging SNPs across CYP17A1, ESR1, CYP19A1, and HSD3B1 in 526 Caucasian men with organ-confined prostate cancer and validated findings in 601 Taiwanese men on androgen-deprivation therapy. After adjusting for known risk factors, CYP17A1 rs6162 was significantly associated with disease progression in both cohorts — hazard ratios of 2.29–4.10 in the Caucasian group (P=0.0014 to 2×10⁻⁷) and HR 3.74 (95% CI 1.71–8.19, P=0.009) in the Taiwanese group. Critically, the rs6162 polymorphism was also linked to plasma DHEA-S levels in Caucasian men (P=0.03), providing a plausible biochemical mechanism: the haplotype tagged by rs6162 influences adrenal androgen output, and elevated DHEA-S fuels intratumoral androgen synthesis even during castration.

Yamada et al. 2013 in Int J Clin Oncol⁵⁵ Yamada et al. 2013 in Int J Clin Oncol
CYP17A1 polymorphisms associated with risk of CRPC in Japanese men receiving ADT. Int J Clin Oncol 18:711–717 examined 214 Japanese men on hormone therapy and found that rs6162 (among three other CYP17A1 SNPs: rs743572, rs6163, rs1004467) was significantly associated with castration-resistant prostate cancer progression (P<0.05). This cross-ethnic replication — in a population with a 54% A allele frequency versus ~41% in Europeans — strengthens the evidence for a functional role of this haplotype.

Robles-Fernandez et al. 2017 in PLoS One⁶⁶ Robles-Fernandez et al. 2017 in PLoS One
Polymorphisms in sex hormone synthesis and metabolism genes and prostate cancer aggressiveness. PLoS One 12:e0185447 genotyped 311 Caucasian men and found the G allele of rs6162 was associated with PSA levels >10 ng/mL, while the AG+AA genotype group showed association with higher D'Amico risk stratification — suggesting the variant may influence both hormone levels and clinical tumor phenotype.

More recently, Hahn et al. 2025 in Prostate Cancer Prostatic Dis⁷⁷ Hahn et al. 2025 in Prostate Cancer Prostatic Dis
Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis 28:802–808 found CYP17A1 rs6162 among three androgen synthesis gene polymorphisms associated with baseline body composition differences (adiposity) in 186 metastatic CRPC patients on ADT — suggesting the variant's influence on steroid synthesis extends to body composition phenotypes during androgen suppression.

Practical Actions

For men with the A allele, the key implication is altered DHEA-S production and downstream androgen availability. Even in the context of ADT, residual adrenal DHEA-S can be peripherally converted to testosterone and DHT, fueling continued prostate cancer signaling. Measuring baseline DHEA-S provides a direct readout of adrenal androgen output relevant to this haplotype. Abiraterone acetate (a potent CYP17A1 inhibitor) is specifically designed to block this residual adrenal androgen production in CRPC; men with the rs6162 A allele who progress to CRPC may be particularly suited to this mechanism of action.

For the broader reproductive hormones category, altered DHEA-S levels affect both sexes: in women, elevated adrenal DHEA-S is a contributor to androgen excess in PCOS-like phenotypes; in men, it fuels testosterone synthesis throughout life.

Interactions

rs6162 forms a haplotype with rs743572 (T-34C, 5'UTR), rs6163, and rs1004467 within the CYP17A1 locus. The rs743572 variant is the most studied regulatory element in this block and has the broadest literature on breast cancer, endometriosis, and PCOS risk. Studies examining rs6162 frequently co-report rs743572 results; the two SNPs are functionally inseparable in many population analyses. The combined haplotype, more than any individual SNP, determines CYP17A1 expression level and steroid output phenotype.

Your skin is not just packaging — it is an active immune organ, and at its center sits filaggrin. The FLG gene encodes profilaggrin¹¹ profilaggrin
a massive precursor protein cleaved into 10–12 filaggrin monomers during terminal differentiation of the epidermis, the protein responsible for aggregating keratin filaments into the dense, waterproof matrix of the outermost skin layer (stratum corneum). Filaggrin is then broken down into natural moisturizing factor (NMF)²² natural moisturizing factor (NMF)
a mixture of amino acids, urocanic acid, pyrrolidone carboxylic acid, urea, and ions that maintains stratum corneum hydration and regulates skin pH. The R501X variant (c.1501C>T) introduces a premature stop codon at position 501 of the protein, eliminating filaggrin production entirely from that allele — making it the most consequential single-nucleotide skin barrier variant known³³ the most consequential single-nucleotide skin barrier variant known
FLG loss-of-function mutations represent the strongest identified genetic risk factor for atopic dermatitis and ichthyosis vulgaris.

The Mechanism

Filaggrin haploinsufficiency (one non-functional copy) substantially reduces filaggrin protein levels, directly impairing barrier assembly and NMF production. The downstream consequences cascade across multiple systems. Without adequate NMF, transepidermal water loss (TEWL) increases, stratum corneum hydration falls, and skin pH rises above the optimal acidic range (pH 4.5–5.5). An alkaline skin surface dysregulates serine protease activity, accelerates corneocyte shedding, and impairs the acidic mantle's natural suppression of Staphylococcus aureus colonization. Structural gaps between corneocytes allow environmental allergens — house dust mite, pollen, food proteins⁴⁴ house dust mite, pollen, food proteins
Percutaneous sensitization through the defective barrier is the primary route for IgE sensitization and food allergy in FLG-null carriers — to penetrate into the viable epidermis, triggering IgE sensitization and Th2-skewed immune responses. This is the molecular foundation of the "atopic march."

The Evidence

R501X was identified in 2006 as the primary cause of ichthyosis vulgaris⁵⁵ ichthyosis vulgaris
a common inherited skin condition causing fish-scale dryness and rough skin and simultaneously as a major predisposing factor for atopic dermatitis⁶⁶ major predisposing factor for atopic dermatitis. The inheritance pattern is semidominant: heterozygotes show mild or no ichthyosis but substantially elevated eczema risk, while homozygotes and compound heterozygotes (carrying R501X on one chromosome and another FLG null allele such as 2282del4 on the other) exhibit overt ichthyosis and severe eczema.

A meta-analysis of 11 studies⁷⁷ meta-analysis of 11 studies
Baurecht et al. 2007: meta-analysis confirming OR 4.09 for FLG null mutations and atopic eczema from case-control studies established the odds ratio for atopic eczema as 4.09 (95% CI 2.64–6.33) from case-control data and 2.06 (95% CI 1.76–2.42) from family studies. A subsequent meta-analysis of 24 studies⁸⁸ meta-analysis of 24 studies
Rodríguez et al. 2009: FLG mutations are robust risk factors for eczema (OR 3.12) and eczema-associated asthma (OR 3.29) confirmed eczema risk (OR 3.12; 95% CI 2.57–3.79) and found that asthma risk is primarily driven by the eczema-asthma compound phenotype (OR 3.29; 95% CI 2.84–3.82), supporting percutaneous sensitization as the dominant mechanism.

FLG carriers face an elevated risk of eczema herpeticum⁹⁹ eczema herpeticum
a severe, potentially life-threatening herpes simplex virus infection of eczematous skin — the frequency of R501X was three times higher in eczema herpeticum patients than in eczema patients without this complication (25% vs 9%, OR 3.4). The variant also promotes Staphylococcus aureus colonization through impaired antimicrobial peptide function and disrupted skin pH.

A randomized controlled trial¹⁰¹⁰ randomized controlled trial
Simpson et al. 2014 JACI: daily emollient from birth reduced cumulative AD incidence by 50% in high-risk infants over 6 months demonstrated that daily emollient application from birth reduced cumulative atopic dermatitis incidence by approximately 50% in high-risk infants — providing direct evidence that barrier augmentation can interrupt the atopic march at its earliest stage.

Practical Actions

The central actionable insight from R501X carrier status is that the skin barrier needs external support that a non-carrier's skin provides internally. For carriers with existing eczema, ceramide-dominant emollients containing the physiologic 3:1:1 ratio of ceramides to cholesterol to free fatty acids most closely replicate what a functional stratum corneum would produce. Urea-containing emollients (10–25% urea) are specifically beneficial because urea is both an NMF component and promotes residual FLG expression — addressing the deficit from two angles. Fragrance, preservatives (especially methylisothiazolinone), and sodium lauryl sulfate in skincare products all exacerbate barrier disruption disproportionately in FLG carriers and should be avoided.

Heterozygous carriers who are not currently eczematous should consider proactive moisturizing during skin stress periods (low humidity, cold weather, frequent handwashing, swimming) to prevent barrier compromise that could initiate sensitization.

For parents carrying R501X: early, consistent emollient use in newborns at family risk is supported by RCT evidence for eczema prevention. Early oral introduction of allergenic foods (peanut, egg) — consistent with current LEAP-trial-informed guidelines — is particularly important in FLG carrier families because percutaneous sensitization through the defective barrier precedes oral tolerance and can establish food allergy before intentional food introduction.

Interactions

The two most common European FLG loss-of-function variants, R501X (rs61816761) and 2282del4 (rs558269137), interact as compound heterozygotes. An individual carrying one copy of each on separate chromosomes has no functional FLG gene — equivalent to homozygosity — and shows the most severe phenotype: overt ichthyosis vulgaris, high-penetrance eczema, and substantially elevated asthma risk. This compound heterozygous state is the most clinically significant FLG interaction.

Interaction between FLG null carrier status and early food sensitization creates a synergistic effect on asthma risk that exceeds the sum of independent effects. This means that preventing IgE food sensitization (through early allergen introduction) in FLG-carrier infants is particularly high-impact.

If both R501X (rs61816761) and 2282del4 (rs558269137) are carried — one on each chromosome — the individual is compound heterozygous and effectively FLG-null, with complete filaggrin absence. This is the most severe FLG genotype and warrants intensive daily ceramide-dominant emollient therapy (twice daily minimum), dermatology referral for personalized management, proactive monitoring for eczema herpeticum, early allergen introduction in offspring, and strict avoidance of all barrier-disrupting personal care ingredients (fragrance, methylisothiazolinone, sodium lauryl sulfate, propylene glycol).

Every red blood cell that reaches the end of its 120-day lifespan releases haemoglobin, which breaks down into biliverdin and then bilirubin¹¹ bilirubin
a yellow pigment that must be conjugated with glucuronic acid by UGT1A enzymes to become water-soluble and excretable in bile. The UGT1A gene cluster on chromosome 2q37 encodes nine UDP-glucuronosyltransferase enzymes — UGT1A1 through UGT1A10 — all sharing exons 2–5 but each with a unique exon 1 that confers distinct substrate preferences. rs6742078 sits in an intronic region of UGT1A10, near the 3′ end of the cluster (chr2:233,763,993, GRCh38), but the variant's GWAS signal spans the entire cluster and tracks most strongly with UGT1A1-mediated bilirubin glucuronidation.

The T allele acts as a proxy marker for reduced-activity haplotypes at UGT1A1 — the enzyme responsible for ~95% of bilirubin conjugation in humans. Carrying one or two T alleles shifts the individual bilirubin setpoint upward, producing mildly elevated unconjugated bilirubin without liver damage. This condition, when sufficiently elevated, is termed Gilbert syndrome²² Gilbert syndrome
a benign constitutional hyperbilirubinemia affecting 3–10% of Western populations.

The Mechanism

The UGT1A cluster uses a unique splicing architecture: a shared promoter drives alternative exon 1 usage, so variants anywhere in the cluster can affect regulation of multiple family members simultaneously. rs6742078 lies 9,307 bp from the end of UGT1A10 and likely exerts its effects through linkage disequilibrium with functional variants in the UGT1A1 promoter or coding sequence — most prominently, the TA-repeat polymorphism (UGT1A1*28) and coding variants including Gly71Arg (rs4148323, UGT1A1*6). These functional variants reduce the enzyme's rate of bilirubin glucuronidation, causing unconjugated bilirubin to accumulate in plasma.

The downstream consequence in the biliary system is that elevated unconjugated bilirubin spills into bile at higher concentrations, exceeding its solubility threshold and promoting nucleation of calcium bilirubinate crystals³³ nucleation of calcium bilirubinate crystals
the seed particles that grow into black pigment gallstones. This is a dose-dependent chemical process: the higher the bilirubin, the greater the supersaturation of bile, and the greater the stone-formation risk.

The Evidence

Bilirubin levels: The landmark meta-analysis of 9,464 participants from three European cohorts⁴⁴ meta-analysis of 9,464 participants from three European cohorts
Johnson et al. Human Molecular Genetics, 2009 identified the UGT1A1 locus as the dominant genetic determinant of serum bilirubin, explaining ~18% of total variation — an exceptionally large proportion for a quantitative trait. The association p-value was <5×10⁻³²⁴, effectively impossible to obtain by chance. A subsequent GWAS in 10,282 Han Chinese⁵⁵ GWAS in 10,282 Han Chinese
Dai et al. Genetic Epidemiology, 2013 confirmed rs6742078 at combined P=1.44×10⁻⁸⁹, explaining 9.2% of bilirubin variation in East Asians.

Gallstone disease (causal, Mendelian randomization): Stender et al. JAMA Internal Medicine, 2013⁶⁶ Stender et al. JAMA Internal Medicine, 2013 used rs6742078 as a Mendelian randomization instrument in 61,212 Danish participants followed for up to 34 years. The T allele raised bilirubin by 16% per copy, with TT homozygotes averaging 90% higher bilirubin than GG homozygotes. Over 34 years, 3,374 participants developed symptomatic gallstone disease: GT heterozygotes had HR 1.09 (95% CI 1.02–1.17) and TT homozygotes HR 1.22 (95% CI 1.09–1.36) versus GG. Because Mendelian randomization uses a randomly assigned genetic instrument, these hazard ratios are interpreted as causal — elevated bilirubin itself is lithogenic, not merely a marker.

Sex-specific gallstone risk: Buch et al. Gastroenterology, 2010⁷⁷ Buch et al. Gastroenterology, 2010 found a striking sex difference in 2,606 German cases and 1,121 controls: male TT homozygotes had OR 2.34 (P=2.1×10⁻⁷) for gallstone disease, while women showed no significant association (P=0.47). The sex-specific finding replicated in South American samples (OR 2.19 in men, P=0.046; no effect in women). Combined, the UGT1A and ABCG8 loci attributed 21.2% of population- attributable risk in men. The biological basis of sex specificity is not fully understood, but oestrogen independently promotes cholesterol saturation in bile, potentially masking the bilirubin-mediated pathway in women while amplifying it in men who lack this alternative lithogenic mechanism.

Circulating cell-free DNA: An unanticipated finding from a GWAS of cell-free DNA levels⁸⁸ GWAS of cell-free DNA levels
Jylhävä et al. PLoS One, 2012 was that all 110 genome-wide significant SNPs for serum cf-DNA mapped to the UGT1A locus on 2q37, strongly implicating UGT1A1-associated glucuronidation pathways in the clearance of extracellular DNA from circulation.

Practical Actions

The TT genotype confers a clear, modifiable gallstone risk. Black pigment gallstones (the type driven by elevated unconjugated bilirubin) can cause biliary colic, cholecystitis, and pancreatitis when they obstruct the bile duct. Monitoring bilirubin and using targeted lifestyle and dietary measures to reduce gallstone nucleation is the evidence-based management approach.

For heterozygous GT carriers, the bilirubin increase (~16%) is modest. Awareness and periodic bilirubin monitoring during routine blood work is sufficient; no specific interventions are required unless other risk factors for gallstones are present.

Interactions

UGT1A1 coding variants (rs4148323): rs6742078 acts as a tag SNP for the broader UGT1A reduced-activity haplotype. Individuals who carry both rs6742078 T alleles and the UGT1A1*6 variant (rs4148323 A allele, common in East Asians) or UGT1A1*28 (rs887829, common in Europeans and Africans) have compounded reduction in bilirubin glucuronidation, producing more severe hyperbilirubinemia and greater gallstone risk. These combinations represent true Gilbert syndrome.

SLCO1B3 (rs2417940): This organic anion transporter on chromosome 12p12 handles hepatic uptake of bilirubin and other organic anions. In the same Chinese GWAS, rs2417940 explained an additional 0.9% of bilirubin variation. Combined reduced-activity genotypes at both loci may produce additive hyperbilirubinemia, though direct interaction data for this pair are limited.

The LDL receptor (LDLR) is the liver's primary tool for clearing low-density lipoprotein¹¹ low-density lipoprotein
LDL, the so-called "bad cholesterol," which ferries cholesterol through the bloodstream to tissues from the bloodstream. Mutations that disrupt LDLR function are the cause of familial hypercholesterolemia, one of the most common and dangerous inherited cardiovascular conditions. But you don't need a protein-changing mutation to impair LDLR function — rs688, a common polymorphism in exon 12, does it through a more subtle mechanism: altering how efficiently the LDLR gene's messenger RNA is spliced.

This variant — technically Asn591Asn (c.1773C>T) — causes no change to the protein sequence. The codon change (AAC→AAT) still encodes asparagine. Yet rs688 has measurable functional consequences on LDLR levels at the cell surface, LDL uptake, and ultimately plasma cholesterol. It represents a class of genetic variants increasingly recognized as important: synonymous variants that alter gene regulation rather than protein structure.

The Mechanism

LDLR pre-mRNA undergoes alternative splicing that can include or skip exon 12. When exon 12 is retained, the normal full-length LDLR receptor is produced. When it is skipped, a truncated, non-functional receptor is generated that is degraded by nonsense-mediated decay²² nonsense-mediated decay
NMD, a cellular quality-control mechanism that destroys mRNAs containing premature stop codons.

The rs688 C>T change neutralizes a putative exon splicing enhancer³³ putative exon splicing enhancer
ESE, a short sequence motif within the exon that recruits splicing factors to ensure the exon is included in the mature mRNA within exon 12. Without this enhancer signal, the splicing machinery is less likely to include exon 12 — reducing the fraction of LDLR mRNA that encodes functional receptor.

Gao et al. (2013)⁴⁴ Gao et al. (2013)
A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function, Human Molecular Genetics measured the downstream consequences in HepG2 liver cells: the minor (T) allele caused a 21.8% reduction in LDLR protein at the cell surface (P=0.012), a 25.7% increase in lysosomal mislocalization (P=0.037), and a 24.3% reduction in LDL uptake (P<0.01). The variant also impaired LDLR endosomal recycling and reduced binding to PCSK9, the regulator that controls LDLR degradation.

The splicing effect is quantified precisely: Lee et al. (2014)⁵⁵ Lee et al. (2014)
Mutual effect of rs688 and rs5925 in regulating low-density lipoprotein receptor splicing, DNA and Cell Biology showed that the T allele reduces exon 12 splicing efficiency by 9.36%±2.58% per allele. When combined with rs5925 (another LDLR polymorphism in the same haplotype block), the compound TT/TC haplotype produces the lowest splicing efficiency (68.54%±1.38%), compared to 79.60%±1.38% for the CC/CC haplotype.

This splicing reduction is also regulated by cellular sterol levels. Medina et al. (2011)⁶⁶ Medina et al. (2011)
Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake, PLoS One showed that cells normally increase LDLR exon 12 inclusion in response to low cholesterol — a feedback mechanism that boosts receptor production when cells need more cholesterol. In rs688 T allele carriers, this sterol-induced splicing regulation is blunted, impairing the body's ability to compensate for low-cholesterol states.

The Evidence

The clinical evidence connects splicing impairment to elevated LDL and cardiovascular risk. Zhu et al. (2007)⁷⁷ Zhu et al. (2007)
A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol, Human Molecular Genetics used the Framingham Offspring Study population to demonstrate that rs688 T allele carriers had approximately 10% higher total and LDL cholesterol than C allele homozygotes in pre-menopausal women. The effect was sex-dependent: it was absent or weak in men and post-menopausal women, suggesting that estrogen modulates the splicing mechanism or the downstream response to LDLR reduction.

Zou et al. (2008)⁸⁸ Zou et al. (2008)
Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease, Human Molecular Genetics found the opposite sex dependence in neural tissue: in brain samples from aged individuals, the T allele was associated with decreased LDLR exon 12 splicing efficiency specifically in males, not females. This tissue- and sex-dependent variation suggests the variant's effect depends on the splicing factor environment, which differs between liver and brain and varies with sex hormones.

At the cardiovascular disease level, a 2026 study from Bangladesh by Hossain et al.⁹⁹ Hossain et al.
Association of the rs688 Polymorphism in LDLR with Coronary Artery Disease, Genetics Research examined 225 participants (150 CAD patients, 75 controls) and found TT genotype carriers had 3.6-fold higher odds of coronary artery disease (OR=3.617, 95% CI: 1.089–10.05, P=0.035), with significantly elevated LDL cholesterol in TT and CT genotypes compared to CC. This study is limited by its small sample size and single-population design, but the direction of effect is consistent with the mechanistic evidence.

The GWAS Catalog records multiple genome-wide significant associations between rs688 and LDL and total cholesterol levels across large multi-ancestry studies (P=5×10⁻³⁰ for LDL, P=4×10⁻²⁸ for total cholesterol), confirming at population scale what the mechanistic studies show at the molecular level.

Practical Implications

The rs688 T allele is common — about 43% globally in European populations — so TT homozygosity (roughly 18% of Europeans) is not a rare finding. Unlike the rare LDLR mutations causing classical familial hypercholesterolemia, rs688 produces a modest per-allele effect. However, the magnitude of LDL elevation (~10% in susceptible individuals) is clinically relevant: a 10% LDL increase corresponds roughly to a 10-15% increase in cardiovascular event risk over a lifetime.

For TT homozygotes, the practical implications are earlier attention to lipid panels and consideration of lifestyle and pharmacological interventions at lower LDL thresholds than might be applied to the general population. The sex-dependent effects suggest pre-menopausal women carrying TT may be disproportionately affected and should be the highest-priority group for monitoring.

rs688 does not cause familial hypercholesterolemia and is classified as benign in ClinVar for that specific condition — meaning it is not a high-penetrance mutation that guarantees disease. It is best understood as a common functional variant that modestly shifts the LDL distribution upward and, at the population level, contributes meaningfully to cardiovascular risk.

Interactions

rs688 interacts with rs5925, another LDLR exon 12 polymorphism. The two variants regulate splicing cooperatively: the compound haplotype carrying both T alleles (rs688-T / rs5925-T) produces the lowest splicing efficiency (68.54%), while the C/C haplotype produces the highest (79.60%). When both variants are present in the same individual, the splicing deficit is additive.

LDLR splicing variants interact broadly with other cholesterol metabolism genes. Carriers of APOE ε4 (rs429358/rs7412) already face impaired LDL clearance due to apolipoprotein E binding differences; rs688-driven LDLR surface reduction compounds this deficit. PCSK9 gain-of-function variants (rs11590235) further reduce LDLR survival on the cell surface — rs688 TT homozygotes carrying a PCSK9 gain-of-function mutation face LDL reduction from two independent mechanisms simultaneously.

In individuals on statins: statins increase LDLR expression by inhibiting cholesterol synthesis and activating SREBP-mediated transcription. However, if rs688 simultaneously reduces the efficiency of LDLR pre-mRNA splicing, the net LDLR surface increase from statin therapy may be blunted relative to individuals with the CC genotype — an interaction worth exploring in pharmacogenomics research.

rs7454108 is a tag SNP¹¹ tag SNP
A genetic marker in near-perfect linkage disequilibrium with another variant, allowing it to serve as a proxy with >99% sensitivity and specificity that identifies the HLA-DQ8 haplotype with extraordinary precision. Located in the intergenic region²² intergenic region
DNA sequence between genes, often containing regulatory elements between HLA-DQB1 and HLA-DQA2 on chromosome 6, this SNP's C allele serves as a genetic "flag" for the presence of HLA-DQB1*03:02, the defining allele of the DQ8 haplotype. The HLA-DQ8 molecule is a heterodimer³³ heterodimer
A protein complex made of two different subunits encoded by DQA1*03:01 and DQB1*03:02, and its presence dramatically increases risk for two major autoimmune diseases: celiac disease and type 1 diabetes.

The Mechanism

The HLA (Human Leukocyte Antigen) system is the body's primary method for distinguishing self from non-self. HLA-DQ molecules sit on the surface of antigen-presenting cells⁴⁴ antigen-presenting cells
Specialized immune cells that display protein fragments to T cells, where they present protein fragments (peptides) to T cells for immune surveillance. HLA-DQ8 has a unique structural pocket that binds and presents gluten peptides from wheat, barley, and rye with high affinity, triggering an inappropriate immune response in susceptible individuals. Studies show⁵⁵ Studies show
Tollefsen et al. characterized DQ8-restricted gluten T cell epitopes and their deamidation requirements. J Clin Invest, 2006 that HLA-DQ8 molecules are particularly efficient at presenting immunodominant gliadin peptides after they've been deamidated⁶⁶ deamidated
Modified by the enzyme tissue transglutaminase, increasing immunogenicity by tissue transglutaminase.

For type 1 diabetes, HLA-DQ8 presents pancreatic β-cell autoantigens⁷⁷ pancreatic β-cell autoantigens
Self-proteins from insulin-producing cells including insulin, GAD65, and ZnT8 to autoreactive T cells. The highest risk genotype is DR3/4-DQ8 heterozygosity⁸⁸ heterozygosity
Carrying one copy of DQ2.5 (from DR3 haplotype) and one copy of DQ8 (from DR4 haplotype), which allows formation of a unique trans-encoded DQ molecule⁹⁹ trans-encoded DQ molecule
A DQ heterodimer formed by pairing alpha and beta chains from different chromosomes that further amplifies risk.

The Evidence

Monsuur et al. demonstrated¹⁰¹⁰ Monsuur et al. demonstrated
Effective detection of human leukocyte antigen risk alleles in celiac disease using tag single nucleotide polymorphisms. PLoS One, 2008 that rs7454108 identifies HLA-DQ8 carriers with 99.1% sensitivity and 99.6% specificity in European populations. This tag SNP is so reliable that it forms the basis of 23andMe's FDA-cleared¹¹¹¹ 23andMe's FDA-cleared
The first direct-to-consumer genetic health risk report cleared by the FDA celiac disease genetic risk report, analyzing rs7454108 alongside rs2187668 (the DQ2.5 tag) to identify the ~95% of celiac patients carrying permissive HLA genotypes.

A 2023 meta-analysis¹²¹² A 2023 meta-analysis
Meta-analysis and systematic review of HLA DQ2/DQ8 in adults with celiac disease. Int J Mol Sci, 2023 found HLA-DQ2 and/or DQ8 in over 95% of celiac disease patients across diverse populations, with HLA-DQ8 alone accounting for 5-10% of cases. In European populations, approximately 12% carry at least one copy of DQ8, but only 1% develop celiac disease, illustrating that HLA-DQ8 is necessary but not sufficient. Studies in siblings¹³¹³ Studies in siblings
Frequency of celiac disease and distribution of HLA-DQ2/DQ8 haplotypes among siblings of children with celiac disease. World J Clin Pediatr, 2022 show 10.7% prevalence among siblings of celiac patients—22.7 times the general population rate—with 98% of affected siblings carrying DQ2 and/or DQ8.

For type 1 diabetes, the evidence is even more dramatic. Barker et al.'s validation study¹⁴¹⁴ Barker et al.'s validation study
Two single nucleotide polymorphisms identify the highest-risk diabetes HLA genotype. Diabetes, 2008 in over 5,000 subjects from the Type 1 Diabetes Genetics Consortium found rs7454108 C allele present in 98.9% of individuals carrying DQB1*0302. The landmark PNAS study¹⁵¹⁵ The landmark PNAS study
Extreme genetic risk for type 1A diabetes. PNAS, 2006 by Aly et al. revealed that DR3/4-DQ8 siblings sharing both HLA haplotypes identical by descent¹⁶¹⁶ identical by descent
Inherited from the same parental chromosomes as their diabetic sibling with their diabetic proband had an 85% risk of developing islet autoantibodies by age 15, compared to 20% in those not sharing both haplotypes. Subsequent research¹⁷¹⁷ Subsequent research
Erlich et al. analysis of Type 1 Diabetes Genetics Consortium families confirmed DR4-DQ8 haplotype risk confirmed HLA-DRB1*04:01-DQB1*03:02 (DR4-DQ8) carries an odds ratio of 8.39 for type 1 diabetes.

Practical Implications

This SNP's primary clinical utility is in ruling out disease rather than predicting it. A TT genotype (no DQ8 copies) combined with absence of DQ2.5 makes celiac disease highly unlikely—approximately 98-99% negative predictive value. This can spare individuals from unnecessary small bowel biopsies¹⁸¹⁸ small bowel biopsies
Gold standard diagnostic procedure requiring endoscopy and tissue sampling when celiac disease is being considered. However, carrying one or two C alleles does not mean you will develop these conditions—it simply means you're genetically eligible.

For celiac disease, environmental factors matter enormously: gluten exposure timing in infancy, gut microbiome composition, and viral infections¹⁹¹⁹ viral infections
Particularly enteroviruses, which may trigger loss of oral tolerance to gluten may all influence whether genetic risk translates to active disease. For type 1 diabetes, additional non-HLA genes (insulin gene VNTR, PTPN22, CTLA4) and environmental triggers work in concert with HLA risk.

If you carry HLA-DQ8 and have first-degree relatives with celiac disease or type 1 diabetes, or if you experience unexplained symptoms²⁰²⁰ symptoms
Chronic diarrhea, bloating, iron-deficiency anemia, fatigue, weight loss for celiac; excessive thirst, frequent urination, unexplained weight loss for type 1 diabetes, genetic testing combined with serological screening (tissue transglutaminase antibodies for celiac, islet autoantibodies for type 1 diabetes) is warranted.

Interactions

The most clinically significant interaction is between rs7454108 (HLA-DQ8 tag) and rs2187668 (HLA-DQ2.5 tag). Individuals who are compound heterozygous²¹²¹ compound heterozygous
Carrying one copy each of DQ2.5 and DQ8 face heightened risk for both celiac disease and type 1 diabetes compared to carrying either haplotype alone. For celiac, this DQ2.5/DQ8 combination is second only to DQ2.5 homozygosity in risk magnitude. For type 1 diabetes, the DR3/4-DQ8 genotype (tagged by rs2187668 heterozygous + rs7454108 heterozygous) represents the highest genetic risk, accounting for 30-50% of childhood-onset cases. The trans-encoded DQ molecule²²²² trans-encoded DQ molecule
DQA1*05:01 from DR3 paired with DQB1*03:02 from DR4 formed in DR3/4-DQ8 individuals may have unique peptide-binding properties that amplify autoimmune risk beyond the sum of individual haplotypes.

A compound implication should be created for individuals carrying both DQ2.5 (rs2187668 CT or TT) and DQ8 (rs7454108 CT or CC), as the combined genotype warrants earlier and more intensive screening for both celiac disease and type 1 diabetes, particularly in individuals with affected family members or suggestive symptoms. The recommendation would be periodic serological screening and heightened clinical vigilance, rather than the "unlikely to develop disease" reassurance appropriate for individuals lacking both risk haplotypes.